Short communicationImmunocryosurgery for non-superficial basal cell carcinomas ≤ 20 mm in maximal diameter: Five-year follow-up
Section snippets
Background
Surgery with histopathological control of resection margins is currently the standard of care for the treatment of uncomplicated basal cell carcinoma (BCC). Micrographic controlled (Mohs') surgery is recommended for relapses or larger tumors with centrofacial localization [1]. Non-surgical modalities are reserved for the treatment of non-invasive superficial tumors [1] or as palliative approaches, due to generally inferior tumor clearance and increased relapse rates. Among others, these
Materials and Methods
By May 31, 2015 all patients recruited in the initial trial NCT01212562 [3] and reported herein had reached at least five years potential follow up. Thus, cohort information was actualized up to July 31th 2016 and is presently reported. The study (trial registration: NCT01212562) was approved by the University Hospital of Ioannina Scientific Committee (Ethics and Clinical Trials Review Section) according to the Declaration of Helsinki Principles [approval number: 4/8-4-2007 (θ.18)]. Study
Results
Four initially recruited patients with five tumors (4.0% of the per ITT tumor sites [3]) did not comply with major treatment prerequisites and were excluded from per protocol analysis. Data on the outcome of the therapeutic intervention for a follow up period of at least five years (≥60 months) after initial treatment were available for 55% of the patients; 9% of the patients deceased and 36% were lost to reexamination prior to completing the five years follow-up. The mean age (±standard
Discussion
The present five year follow up data further confirm the efficacy of immunocryosurgery for non-superficial basal cell carcinomas ≤20 mm in maximal diameter, irrespective of their localization and histology. With a five-year tumor clearance rate of 91.4 ± 2.8% after a single treatment cycle (97.1 ± 1.6% after retreatment of therapy failures) immunocryosurgery is not inferior to surgical modalities for this neoplasm [5,6]. Notably, reports of Mohs' surgery for BCC included tumors of largely
Ethics Approval and Consent to Participate
The original study (trial registration: NCT01212562) was approved by the University Hospital of Ioannina Scientific Committee (Ethics and Clinical Trials Review Section) according to the Declaration of Helsinki Principles: Approval number: 4/8-4-2007 (θ.18).
Consent for Publication
The patients presented in Fig. 3 cannot be recognized or identified, yet we have obtained written informed consent for the presentation of their clinical pictures that will be freely available on the internet and may be seen by the general public.
Competing Interests
Both authors have received travel grants from MEDA, Hellas, to present relevant data at international and local conferences.
Funding
This study was partially supported by the Special Research Committee Account of University of Ioannina No. 22195.
Authors' Contributions
GG gathered the clinical information and wrote the first draft of the manuscript. IDB designed the study, performed the statistics and critically revised the manuscript.
Acknowledgements
None.
References (10)
- et al.
Factors associated with postoperative complications in elderly patients with skin cancer: a retrospective study of 241 patients
J Geriatr Oncol
(2016) - et al.
Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomized controlled trial with 5-years' follow-up
Lancet Oncol
(2008) - et al.
Basal cell carcinoma treated with Mohs surgery in Australia II. Outcome at 5-year follow-up
J Am Acad Dermatol
(2005) - et al.
Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomized controlled trial
Lancet Oncol
(2014) - et al.
Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: a randomised clinical trial with 10year follow-up
Eur J Cancer
(2014)
Cited by (15)
Cryoablation and immunotherapy of cancer
2020, Current Opinion in BiotechnologyCitation Excerpt :Local application of cryoablation and systemic administration of anti-PD-1 lead to anti-tumor immune responses and delayed tumor growth of distant untreated tumors in a model of renal cell carcinoma, suggestive of abscopal effects [31]. Basal cell carcinoma patients treated with imiquimod (TLR7/8 agonist) and cryoablation exhibited 91% recurrence-free survival in a 5-year follow-up [32]. Similar results were reported from an ongoing clinical trial that employed anti-CTLA-4 and anti-PD-1 alongside cryoablation in patients with breast cancer [33].
A single-centre retrospective comparison of immunocryosurgery with standard surgical excision for the treatment of non-superficial, head and neck basal cell carcinoma
2024, Journal of the European Academy of Dermatology and VenereologyProgress in the cryoablation and cryoimmunotherapy for tumor
2023, Frontiers in ImmunologyPD-1 monoclonal antibodies enhance the cryoablation-induced antitumor immune response: a breast cancer murine model research
2023, International Journal of Hyperthermia